| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
Purity: ≥98%
| ln Vitro |
Mebutamate is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.
|
|---|---|
| ln Vivo |
The comparative potency of phenobarbital and five 1,3-propanediol dicarbamates for hepatic cytochrome P450 induction in rats. Using a reproducible screening procedure for rat liver cytochrome P450 isoenzyme induction/inhibition, five dicarbamate drugs (meprobamate, mebutamate, carisoprodol, tybamate, and W-554) were compared with sodium phenobarbital and found to be from 25 to 100 times less potent hepatic cytochrome P450 inducers than phenobarbital [1].
|
| Animal Protocol |
The mechanism of the hypotensive action of mebutamate was investigated in cross-circulation experiments in anesthetized dogs. Pressor responses were elicited in the recipient’s body by electrical stimulation of the medullary vasomotor center of the vascularly isolated head. These pressor responses were not modified when mebutamate, 20 mg/kg, i.v., was given to the donor dog, but were markedly reduced when the agent was similarly given to the recipient’s body circulation. In anesthetized cats mebutamate often reduced the resting splanchnic nerve activity and the discharge evoked by vasomotor center stimulation. In addition, mebutamate exhibited a moderate blocking action on the autonomic ganglia. Intraarterial injections of mebutamate, 2 mg, in dogs also caused a prompt and marked increase in femoral arterial blood flow, unaffected by chronic sympathectomy or administration of atropine and/or pronethalol. The hypotensive action of mebutamate is thus attributed to both a direct vasodilator effect and an inhibition of the sympathetic vasomotor outflow. The former appears to be responsible for the initial, transient and prompt fall in the blood pressure, and the latter for the sustained vasomotor depression essentially at the spinal and ganglionic sites [2].
|
| References |
[1]. Res Commun Chem Pathol Pharmacol. 1985 Jun;48(3):467-70.
[2]. J Pharmacol Exp Ther. 1966 Feb;151(2):285-93. |
| Additional Infomation |
Mebutamate is an organic molecular entity.
Mebutamate is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance. Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a sedative. Side effects include dizziness and headaches. |
| Molecular Formula |
C10H20N2O4
|
|---|---|
| Molecular Weight |
232.28
|
| Exact Mass |
232.142
|
| CAS # |
64-55-1
|
| PubChem CID |
6151
|
| Appearance |
Solid powder
|
| Density |
1.114g/cm3
|
| Boiling Point |
435ºC at 760 mmHg
|
| Melting Point |
90-94°C
|
| Flash Point |
216.8ºC
|
| Index of Refraction |
1.477
|
| LogP |
2.63
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
16
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N([H])[H])=O)C([H])([H])C(C([H])([H])[H])(C([H])([H])OC(N([H])[H])=O)C([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
LEROTMJVBFSIMP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)
|
| Chemical Name |
[2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate
|
| Synonyms |
Dormate; Capla; Mebutamate
|
| HS Tariff Code |
2924199090
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: > 10 mM
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3051 mL | 21.5257 mL | 43.0515 mL | |
| 5 mM | 0.8610 mL | 4.3051 mL | 8.6103 mL | |
| 10 mM | 0.4305 mL | 2.1526 mL | 4.3051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA